Rivastigmine as an Antidote for Clozapine and Other Anticholinergic-Induced CNS Depression and Delirium: A Study of 100 Cases

This study aims to evaluate the clinical efficacy and safety of rivastigmine in reversing the full spectrum of anticholinergic delirium including hypoactive delirium which is presented with CNS depression and hyperactive or agitated delirium. The study was conducted on 100 patients at the Poison Control Center of Alexandria University Main Hospital. The primary objective is to assess the effectiveness of rivastigmine in restoring consciousness and improving cognitive function in patients presenting with delirium and depressed mental status using GCS and RASS score.

NCT Number	NCT07545382
Lead Sponsor	Alexandria University
Conditions	Anticholinergic Delirium, Clozapine Poisoning, Antipsychotic Toxicity, CNS Depression, Hypoactive Delirium, Tricyclic Antidepressant Poisoning, Procyclidine Induced Delirium
Enrollment	100 participants
Start Date	2025-12-08
Primary Completion	2026-04-15 (estimated)
Study Completion	2026-04-15 (estimated)
Updated on ClinicalTrials.gov	2026-05-19